ROI Financial Advisors LLC Sells 675 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

ROI Financial Advisors LLC reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 16.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,322 shares of the company's stock after selling 675 shares during the period. IDEXX Laboratories makes up about 0.9% of ROI Financial Advisors LLC's holdings, making the stock its 27th largest holding. ROI Financial Advisors LLC's holdings in IDEXX Laboratories were worth $1,373,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Norges Bank acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $412,258,000. Flossbach Von Storch SE raised its position in IDEXX Laboratories by 5,439.3% in the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock valued at $195,696,000 after purchasing an additional 464,791 shares during the period. William Blair Investment Management LLC increased its stake in IDEXX Laboratories by 701.6% during the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock worth $174,527,000 after buying an additional 369,471 shares during the period. Assenagon Asset Management S.A. boosted its holdings in IDEXX Laboratories by 265.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock valued at $179,867,000 after purchasing an additional 316,048 shares during the last quarter. Finally, Seilern Investment Management Ltd bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $113,104,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of recent research reports. Morgan Stanley lowered their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Bank of America raised their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, April 4th. Finally, Barclays increased their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $533.75.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.11% of the company's stock.

IDEXX Laboratories Price Performance

Shares of IDXX stock traded down $19.21 during trading on Thursday, hitting $377.90. The company had a trading volume of 571,707 shares, compared to its average volume of 609,226. The firm has a market capitalization of $30.62 billion, a P/E ratio of 35.42, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $548.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The stock's 50-day moving average price is $431.26 and its 200 day moving average price is $435.73.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.